{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:33:07Z","timestamp":1791469987366,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.htct.2023.07.007","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T19:50:14Z","timestamp":1693252214000},"page":"397-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine"],"prefix":"10.1016","volume":"46","author":[{"given":"Lais Moreira","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-0014","authenticated-orcid":false,"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-1712","authenticated-orcid":false,"given":"Rodrigo Doyle","family":"Portugal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.htct.2023.07.007_bib0001","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.htct.2023.07.007_bib0002","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2023.07.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6464972","article-title":"Outcomes of six-dose high-dose cytarabine as a salvage regimen for patients with relapsed\/refractory acute myeloid leukemia","volume":"2017","author":"Anders","year":"2017","journal-title":"Adv Hematol"},{"key":"10.1016\/j.htct.2023.07.007_bib0004","article-title":"Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia","author":"Li","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.htct.2023.07.007_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-020-04238-5","article-title":"Antibiotic use during cytarabine consolidation in acute myeloid leukemia","volume":"100","author":"Vale","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.htct.2023.07.007_bib0006","doi-asserted-by":"crossref","first-page":"e2560","DOI":"10.1097\/MD.0000000000002560","article-title":"Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a multicenter, prospective, observational study in China","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.htct.2023.07.007_bib0007","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.23440","article-title":"Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?","volume":"88","author":"Wiernik","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.htct.2023.07.007_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-199005010-00003","article-title":"The toxicity of cytarabine","volume":"5","author":"Stentoft","year":"1990","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.htct.2023.07.007_bib0009","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1007\/s00520-018-4292-0","article-title":"Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols","volume":"26","author":"Kato","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.htct.2023.07.007_bib0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dky550","article-title":"\u2018Real-life\u2019 analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study","volume":"74","author":"Del Principe","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.htct.2023.07.007_bib0011","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2000.18.9.1845","article-title":"Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891","volume":"18","author":"Gamis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2023.07.007_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.htct.2019.07.005","article-title":"Current treatment preferences in acute myeloid leukemia: a survey in Brazil","volume":"42","author":"Portugal","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"10.1016\/j.htct.2023.07.007_bib0013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/161.3.397","article-title":"The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel","volume":"161","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.htct.2023.07.007_bib0014","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (accessed on March 10, 2022)."},{"issue":"12","key":"10.1016\/j.htct.2023.07.007_bib0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2023.07.007_bib0016","article-title":"High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.htct.2023.07.007_bib0017","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.1038\/s41598-017-10368-0","article-title":"Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.htct.2023.07.007_bib0018","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2023.07.007_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.24974","article-title":"Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"93","author":"Altman","year":"2018","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.htct.2023.07.007_bib0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"Rollig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.htct.2023.07.007_bib0021","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.20.01170","article-title":"Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses","volume":"39","author":"Burnett","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2023.07.007_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17474086.2017.1280389","article-title":"Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review","volume":"10","author":"Portugal","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.htct.2023.07.007_bib0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.htct.2023.07.007_bib0024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.htct.2023.07.007_bib0025","first-page":"151","article-title":"Safety and feasibility of outpatient high dose cytarabine for acute myeloid leukemia in the Brazilian Amazon","volume":"14","author":"Rodrigues","year":"2020","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"16","key":"10.1016\/j.htct.2023.07.007_bib0026","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/bloodadvances.2020002511","article-title":"Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome","volume":"4","author":"Dumas","year":"2020","journal-title":"Blood Adv"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113792300161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113792300161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:37:08Z","timestamp":1726612628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S253113792300161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S253113792300161X"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2023.07.007","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2023.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}